Call Options

15 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$40.81 - $55.0 $5.68 Million - $7.65 Million
139,100 Added 148.77%
232,600 $12.2 Million
Q2 2024

Aug 15, 2024

SELL
$35.41 - $44.37 $5.99 Million - $7.51 Million
-169,200 Reduced 64.41%
93,500 $3.84 Million
Q1 2024

May 07, 2024

SELL
$39.12 - $52.44 $324,696 - $435,252
-8,300 Reduced 3.06%
262,700 $11.4 Million
Q4 2023

Feb 14, 2024

BUY
$21.39 - $49.64 $4.7 Million - $10.9 Million
219,600 Added 427.24%
271,000 $12.5 Million
Q3 2023

Nov 14, 2023

BUY
$15.81 - $27.8 $262,446 - $461,480
16,600 Added 47.7%
51,400 $1.18 Million
Q2 2023

Aug 11, 2023

SELL
$16.32 - $21.15 $1.15 Million - $1.49 Million
-70,300 Reduced 66.89%
34,800 $573,000
Q1 2023

May 16, 2023

BUY
$16.88 - $34.24 $499,647 - $1.01 Million
29,600 Added 39.21%
105,100 $1.87 Million
Q4 2022

Feb 14, 2023

SELL
$22.21 - $30.25 $4.5 Million - $6.13 Million
-202,700 Reduced 72.86%
75,500 $2.2 Million
Q3 2022

Nov 14, 2022

BUY
$4.3 - $30.85 $724,550 - $5.2 Million
168,500 Added 153.6%
278,200 $6.82 Million
Q2 2022

Aug 15, 2022

BUY
$3.12 - $12.25 $16,224 - $63,700
5,200 Added 4.98%
109,700 $455,000
Q1 2022

May 16, 2022

BUY
$6.13 - $12.24 $294,240 - $587,520
48,000 Added 84.96%
104,500 $1.2 Million
Q4 2020

Feb 16, 2021

BUY
$21.17 - $32.61 $990,756 - $1.53 Million
46,800 Added 482.47%
56,500 $1.68 Million
Q3 2020

Nov 16, 2020

BUY
$18.13 - $30.61 $175,861 - $296,917
9,700 New
9,700 $210,000
Q4 2019

Feb 14, 2020

SELL
$19.53 - $25.5 $193,347 - $252,450
-9,900 Closed
0 $0
Q3 2019

Nov 14, 2019

BUY
$18.62 - $24.51 $184,338 - $242,649
9,900 New
9,900 $214,000

Others Institutions Holding RYTM

About RHYTHM PHARMACEUTICALS, INC.


  • Ticker RYTM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,720,000
  • Market Cap $3.13B
  • Description
  • Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convert...
More about RYTM
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.